GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency | Zendy

Claudia Giavoli | Zendy; Eriselda Profka | Zendy; Elisa Verrua | Zendy; Cristina L. Ronchi | Zendy; Emanuele Ferrante | Zendy; S. Bergamaschi | Zendy; Elisa Sala | Zendy; Elena Malchiodi | Zendy; Andrea Lania | Zendy; Maura Arosio | Zendy; Bruno Ambrosi | Zendy; Anna Spada | Zendy; Paolo BeckPeccoz | Zendy

Open Access

GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency

Author(s) -

Claudia Giavoli,

Eriselda Profka,

Elisa Verrua,

Cristina L. Ronchi,

Emanuele Ferrante,

S. Bergamaschi,

Elisa Sala,

Elena Malchiodi,

Andrea Lania,

Maura Arosio,

Bruno Ambrosi,

Anna Spada,

Paolo BeckPeccoz

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2477

Subject(s) - acromegaly , hypopituitarism , medicine , insulin resistance , growth hormone deficiency , body mass index , endocrinology , quality of life (healthcare) , insulin tolerance test , anthropometry , pituitary adenoma , impaired glucose tolerance , insulin , adenoma , hormone , growth hormone , nursing , insulin sensitivity

Objective: Effects of GH replacement in patients with GH deficiency (GHD) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. The aim of the study was to evaluate whether metabolic parameters and quality of life are improved by GH replacement in patients with prior acromegaly and severe GHD. Design and Methods: This was a prospective study on 42 GHD subjects [22 men, mean age (sd): 48 ± 10]: 10 acromegalics treated with recombinant human GH (group A), 12 acromegalics who refused treatment (group B), and 20 subjects operated for nonfunctioning pituitary adenoma on recombinant human GH (group C). Serum IGF-I levels, lipid profile, glucose levels (fasting and after an oral glucose tolerance test), glycosylated hemoglobin, insulin resistance (homeostasis model assessment insulin resistance index), anthropometric parameters (body mass index, waist circumference, body composition), and quality of life (Questions on Life Satisfaction-Hypopituitarism Z-scores) were evaluated at baseline and after 12 and 36 months. Results: At baseline, group B showed higher IGF sd score than group A and C, as well as better quality of life and higher post-oral glucose tolerance test glucose levels than group A. After 12-months, similarly in group A and C, the IGF-I sd score significantly increased, and body composition and lipid profile improved, without deterioration of glucose tolerance. Quality of life significantly improved too, and the baseline difference between group A and B disappeared. Results were confirmed after 36 months. Conclusions: In GHD acromegalic patients, GH therapy improved body composition, lipid profile, and quality of life as in patients with GHD due to nonfunctioning pituitary adenoma, without negative effects on glucose metabolism. GH replacement therapy should be considered in these patients, as in patients with GHD from other causes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research